Haemanthamine (1-100 μM; 24-48 hours; A2780 cells) treatment shows a time- and dose-dependent decrease in cell viability.Haemanthamine (10 μM; 24-72 hours; A2780 cells) treatment leads to a significant inhibition of A2780 cell proliferation.Haemanthamine binds at the A-site cleft of the peptidyl transferase center on the large ribosomal subunit, creating unique molecular interactions with the 25S rRNA. Haemanthamine has a highly specific inhibitory effect on pre-rRNA processing, leading to the activation of a p53-dependent antitumoral surveillance pathway known as nucleolar stress.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.